Search

Your search keyword '"Anwer, Faiz"' showing total 110 results

Search Constraints

Start Over You searched for: Author "Anwer, Faiz" Remove constraint Author: "Anwer, Faiz" Topic multiple myeloma Remove constraint Topic: multiple myeloma
110 results on '"Anwer, Faiz"'

Search Results

1. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma.

2. TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians.

3. Disparities in time to treatment with oral antimyeloma medications.

4. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.

5. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.

6. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

7. Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation.

8. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.

9. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.

10. Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.

11. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.

12. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma.

13. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.

15. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma.

16. Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection-related hospitalizations in multiple myeloma patients.

18. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.

19. Validation of the role of corrected DLCO in predicting outcomes post autologous hematopoietic cell transplant for multiple myeloma.

20. On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone.

21. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.

22. Advancements and future trends of immunotherapy in light-chain amyloidosis.

23. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.

24. Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase.

25. Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.

26. Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials.

27. Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma.

28. Advances in viral oncolytics for treatment of multiple myeloma - a focused review.

29. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review.

30. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.

32. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.

33. Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy.

34. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.

35. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.

36. Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma.

37. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials.

38. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.

39. Treatment of relapsed multiple myeloma: Evidence-based recommendations.

40. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

41. Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.

42. Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.

43. Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity.

44. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.

45. Emerging immune targets for the treatment of multiple myeloma.

46. Limitations of routine skeletal survey: detection of critical but asymptomatic cervical spine lesion in multiple myeloma.

47. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma.

48. Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.

49. The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review.

50. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.

Catalog

Books, media, physical & digital resources